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ABSTRACT
Background: Established measurements of proliferation in breast cancer are Ki67 
and mitotic-activity-index (MAI), with problems in reproducibility and prognostic 
accuracy. Phosphohistone H3 (PHH3), a relatively novel IHC marker is specific 
for mitosis with good reproducibility. We hypothesized that PHH3 would be more 
reproducible and better represent proliferation than Ki67. 
Results: PHH3 identified easily-missed mitosis by MAI, as demonstrated by 
upgrading M grade at diagnosis (n = 29/218, evenly distributed). PHH3 accurately 
found hot-spots, supported by mitotic count agreement between low-power and 
10HPFs (R2 = 0.999; P = 0.001). PHH3 was more reproducible than Ki67, measured by 
five-rater inter-class correlation coefficient (0.904 > 0.712; P = 0.008). Finally, despite 
a relatively short follow-up (median 46 months; 7 recurrences) PHH3 was the only 
variable correlated with disease-free survival (P = 0.043), while all other conventional 
clinicopathologic variables, including Ki67 (P = 0.356), did not.
Materials and Methods: We compared Ki67 and PHH3 for 218 breast cancer 
surgical cases diagnosed from 2012 to 2013 at Severance hospital. The most 
representative invasive breast cancer surgical slides were immunohistochemically 
stained for Ki67 and PHH3. 
Conclusions: Poor reproducibility and inadequate representation of proliferation 
of Ki67 and MAI may be improved by PHH3, allowing better accuracy in breast cancer 
diagnostics.
INTRODUCTION
Of all human malignancies, breast cancer is 
notorious for heterogeneity, thus difficult to predict 
malignant behavior [1]. Therefore measuring proliferation 
is important to classify and predict biologic behaviors of 
breast cancers. The two best-known methods of measuring 
proliferation are, Ki67 and mitotic activity index (MAI). 
MAI is included in the standard breast cancer pathology 
report as part of the histologic grade and considered the 
most important component to predict prognosis [2]. Ki67 
is commonly used in many laboratories to distinguish 
those with significant risk of relapse to warrant adjuvant 
cytotoxic chemotherapy and is a criterion in breast cancer 
subtyping [3, 4]. However, despite these important 
roles, Ki67 and MAI both have notable weaknesses in 
reproducibility, which is problematic in diagnostics.
In terms of a reliable, reproducible marker 
for diagnostics, Ki67 is particularly problematic 
in heterogeneous tumors as breast cancer, causing 
disagreement in field selection for assessment.  In 
addition, depending on the standards of each rater, Ki67 
may be considered positive for a wide range of stain 
intensities, culminating in poor reproducibility [5]. Another 
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notable weakness of Ki67 is its adequacy in representing 
proliferation. Ki67 is a DNA-binding protein expressed in 
all active phases of the cell cycle (G1, S, and G2 phases). 
Despite universal acceptance of Ki67 as a proliferative 
marker, several studies have disapproved, particularly 
because cells in the G1 phase have shown uncertain 
destinies [6–8]. 
While MAI is deemed best amongst available 
proliferative markers for reflecting proliferative potential 
in the College of American Pathologists’ consensus 
statement in 1999 and the Union for International Cancer 
Control [9, 10], its reproducibility was consistently 
reported unsatisfactory. Factors contributing to low 
reproducibility may be from difficulties in discriminating 
mitotically active areas in Hematoxylin and Eosin (H&E) 
as well as coexistence of cells that mimic mitosis, such 
as hyperchromatic, karyorrhectic, or apoptotic cells, 
which leads to low reproducibility even among trained 
pathologists [11]. 
Such problems in conventional proliferative 
markers may be solved by the use of phosphohistone H3 
(PHH3). Histone H3 is a nuclear core histone protein of 
DNA chromatin, with an important role in chromosome 
condensation and cell-cycle progression during mitosis and 
meiosis after phosphorylation of serine-10 and serine-28 
residues. Phosphorylation occurs during late G2 to early 
prophase, while dephosphorylation occurs slowly from 
late anaphase to early telophase. Therefore in metaphase, 
histone H3 is always heavily phosphorylated and positive 
for PHH3, whereas interphase does not or minimally 
express PHH3 – a property that allows PHH3 to stain only 
mitotically active cells, therefore proliferation-specific [9]. 
PHH3 has been verified in multiple studies 
concerning various tumors (colorectal adenocarcinoma, 
ovarian serous adenocarcinoma, pulmonary neuroendocrine 
carcinoma, uterine smooth muscle tumors, astrocytomas, 
and meningiomas), for its sensitive and specific role as a 
marker of mitotic figures (MFs) and excellent correlation 
with outcome [12–17]. In breast cancer, MAI was also 
strongly correlated with PHH3 [18]. In that study, the 
authors proposed that PHH3 had potential to assist in 
breast cancer grading because PHH3 more accurately 
detects MFs than traditional MAI. Supported by these 
reasons, we hypothesized that PHH3 may be superior to 
the existing marker Ki67 in terms of reproducibility and 
better represent proliferation.
In a similar study by Gerring et al. [19] reported 
that PHH3 was a stronger predictor of survival at 5 years 
after diagnosis than Ki67 (hazard ratio 4.35 > 2.44) and 
better separated risk of death in patients aged >45 years. 
However, the study used Tissue Microarrays (TMAs), 
which is not representative of tumor heterogeneity.
This comparative exploratory study improves on 
previous studies because it was conducted on more than 
200 cases of surgical slides of the most representative 
tumor section, simulating the actual setting of breast cancer 
diagnosis. In addition, we address all problems associated 
with conventional markers of proliferation (MAI and Ki67) 
and compare it to the more novel marker, PHH3. 
RESULTS
Patient characteristics
This study examined 218 consecutive primary breast 
cancer (stage I~III) cases from Jan. 2012 to Dec. 2013 at 
Severance hospital, Seoul, Korea. Age of patients ranged 
from 26 to 83 years (mean 53.8) and mean tumor diameter 
was 1.87 cm (range 1.0–9.0). Three-fourths (76.6%) had 
pathologically negative nodes (Table 1). estrogen receptor 
(ER) and progesterone receptor (PR)positive rates were 78.0 
and 51.8%, respectively; positive rate of HER2 cases was 
15.1%. Distribution of patients according to breast cancer 
subtypes were as follows; Luminal A (105 cases), Luminal 
B (65 cases), HER2 enriched (36 cases), and triple negative 
(12 cases). The median observation period was 46 months.
Expression patterns: Ki67 and PHH3
For each case Ki67 was scored as recommended by 
the International Ki67 in Breast Cancer Working Group 
[20]; four HPFs (objective 40x) that best represented the 
overall tumor were selected from the invasive front. The 
exact same fields of Ki67 were appropriately marked for 
PHH3 (Supplementary Figure 1). Both markers were 
scored by the average percentage of positive cells in those 
four fields. 
There was an overall tendency for Ki67 and PHH3 
to be positively correlated. Histogram and Shapiro–Wilk 
test (P < 0.001) revealed a left-skewed distribution of 
both markers (Figure 1A). Spearman correlation was 0.54 
(P < 0.001), demonstrating a moderately positive linear 
relationship between the two (Figure 1B). 
Overall, PHH3 was expressed in significantly 
fewer cells than Ki67 (mean: 0.393 ± 0.568% < 36.67 ± 
26.08%, P < 0.001). Ki67 had a wide range (min. 0%, 
max. 89.00%; IQR1 11.66%, IQR3 34.09%) while range 
of PHH3 was much narrow (min. 0%, max. 2.22%; IQR1 
0%, IQR3 0.59%). Ki67 had wide range of intensities 
and more frequently expressed in non-tumor cells, 
whereas only a few cells expressed PHH3, usually with 
strong intensities (Figure 2). PHH3 stained cells were 
reconfirmed by morphology (nuclei containing condensed 
chromatin) to accurately count mitotic cells. 
Ki67 and PHH3 cut-off values by contal and 
O’Quigley’s method was chosen
Ki67 and PHH3 cut-off values were chosen by 
Contal and O’Quigley’s method to select the most 
appropriate cut-off based on clinical events (recurrences, 
Supplementary Table 2). Contal and O’Quigely’s method 
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finds the best cutpoint in a continuous variable with 
regards to a survival outcome and time to event based on 
the log rank test statistic. The resulting cut-off of Ki67 
was 43.0% while PHH3 was 0.03%, by which Ki67 and 
PHH3 were converted into categorical variables in low 
and high groups. 
Low and high groups of Ki67 and PHH3 were 
shown to have no significant correlations with traditional 
clinicopathologic parameters (Table 1).
PHH3 had near-perfect inter-rater agreement in 
staining interpretations
To evaluate interpretation of positivity only and 
remove discrepancy caused by selection of different fields 
221 randomly selected photographs taken at HPFs were 
assessed independently by two trained pathologists of 
the same institution. In consideration of the continuous 
nature of values, inter-class correlation coefficient (ICC) 
Table 1: Association between clinicopathologic characteristics and Ki-67, PHH3 expressions
Parameters TotalN = 218 (%)
Ki-67 LI (cut-off: 43.0%) PHH3 (cut-off: 0.30%)
Low gr. (%) High gr. (%) P Low gr. (%) High gr. (%) P
Age (years) 0.477 0.984
≤ 50 88 (40.4) 75 (34.4) 13 (6.0) 52 (23.9) 36 (16.5)
> 50 130 (59.6) 106 (48.6) 24 (11.0) 77 (35.3) 53 (24.3)
Nuclear grade 0.076 0.392
1/2 161 (73.9) 138 (63.3) 23 (10.6) 98 (45.0) 63 (28.9)
3 57 (26.1) 43 (19.7) 14 (6.4) 31 (14.2) 26 (11.9)
Mitotic grade 0.112 0.160
1 137 (62.8) 118 (54.1) 19 (8.7) 86 (39.4) 51 (23.4)
2/3 81 (37.2) 63 (28.9) 18 (8.3) 43 (19.7) 38 (17.4)
Histologic grade 0.060 0.363
I 62 (28.4) 52 (23.9) 10 (4.6) 40 (18.3) 22 (10.1)
II 100 (45.9) 88 (40.4) 12 (5.5) 60 (27.5) 40 (18.3)
III 56 (25.7) 41 (18.8) 15 (6.9) 29 (13.3) 27 (12.4)
Tumor stage 0.150 0.960
T1 149 (68.3) 120 (55.0) 29 (13.3) 88 (40.4) 61 (28.0)
T2/T3 69 (31.7) 61 (28.0) 8 (3.7) 41 (18.8) 28 (12.8)
Nodal metastasis 0.883 0.789
Absent 167 (76.6) 139 (63.8) 28 (12.8) 98 (45.0) 69 (31.7)
Present 51 (23.4) 42 (19.3) 9 (4.1) 31 (14.2) 20 (9.2)
Estrogen receptor 0.093 0.258
Negative 48 (22.0) 36 (16.5) 12 (5.5) 25 (11.5) 23 (10.6)
Positive 170 (78.0) 145 (66.5) 25 (11.5) 104 (47.7) 66 (30.3)
Progesterone 
receptor
0.431 0.388
Negative 105 (48.2) 85 (39.0) 20 (9.2) 59 (27.1) 46 (21.1)
Positive 113 (51.8) 96 (44.0) 17 (7.8) 70 (32.1) 43 (19.7)
HER-2 status 0.481 0.175
Negative 185 (84.9) 155 (71.1) 30 (13.8) 113 (51.8) 72 (33.0)
Positive 33 (15.1) 26 (11.9) 7 (3.2) 16 (7.3) 17 (7.8)
Molecular subtype 0.355 0.192
Luminal A 105 (48.2) 88 (40.4) 17 (7.8) 70 (32.1) 35 (16.1)
Luminal B 65 (29.8) 57 (26.1) 8 (3.7) 34 (15.6) 31 (14.2)
HER-2 36 (16.5) 27 (12.4) 9 (4.1) 19 (8.7) 17 (7.8)
TNBC 12 (5.5) 9 (4.1) 3 (1.4) 6 (2.8) 6 (2.8)
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measured inter-rater agreement. ICC revealed a near-
perfect agreement in both methods (microscope 0.984, 95% 
confidence interval (CI) 0.970–0.991; photographs 0.953, 
95% CI 0.937–0.964), validating PHH3 as a reproducible 
measure in selection of appropriate fields as well as clear 
and unequivocal interpretation of positive cells. 
PHH3 had significantly superior inter-rater 
agreement compared to Ki67, evaluated by five 
raters
Inter-rater agreement of Ki67 was assessed for 
30 Ki67 stained slides on the microscope by five different 
raters (Kim JY, Jeong HS, Chung T, Kim M, Lee JH), 
independently. Each rater rated four consecutive fields of the 
hot-spot area and rated each area for positive cell percentage 
and the average was recorded. The resulting ICC was 0.712 
(95% CI 0.598–0.856), considered good agreement. 
Inter-rater agreement of PHH3 was assessed for 
the same 30 cases as Ki67, independently rated on the 
microscope by the same five raters. Each rater selected 
four consecutive fields of the hot-spot area, equal to the 
method rated for Ki67 and the sum of positive cells was 
recorded. The resulting ICC was 0.904 (95% CI 0.869–
0.960) – excellent agreement.
ICC for both Ki67 and PHH3 were compared 
using the dependent ICC comparisons test, which 
compares dissimilar methods for the same set of cases 
(Supplementary Figure 2). The comparisons test revealed 
that ICC of PHH3 was significantly higher than that of 
Ki67 (0.904 > 0.712; P = 0.008), demonstrating PHH3’s 
superior reproducibility to Ki67. 
PHH3 was more sensitive for detecting mitosis 
than MAI
With the purpose of comparing M grades scored 
by PHH3 and those by H&E (MAI), we counted MFs as 
detected on PHH3 stained slides for 10 contiguous HPFs 
in areas of highest mitotic activity. PHH3-labeled-MFs 
were easily seen and permitted quick identification of hot-
spots. The counted mitotic number was converted to M 
grade of the Nottingham grading system, as follows; grade 
1 for less than or equal to 7 mitoses per 10 HPFs; grade 
2 for 8–14 mitoses per 10 HPFs; grade 3 for equal to or 
greater than 15 mitoses per 10 HPFs. This newly scored 
M grade of PHH3 was compared to the M grade assessed 
by MAI of H&E slides. 
Based on these comparisons, there were more up-
graded than down-graded cases (29 > 17 cases, Table 2) 
compared to M grade at diagnosis. As a sensitive marker 
of mitosis, PHH3 tended to reveal mitosis that were 
overlooked by MAI, which caused up-grading. 17 cases 
which were downgraded upon PHH3 counting were 
predominantly from older blocks, suggesting loss of 
antigen preservation as the cause of down-grading. The 
up-graded 29 cases for PHH3 M grade were evenly 
distributed across the years. This is noteworthy because it 
highlights an inherent problem of the M grade evaluated 
by H&E (MAI), which may under-grade the proliferative 
potential of tumor by under-detection of mitosis. 
PHH3 accurately identified mitotic hot spots at 
low power
To demonstrate efficacy of PHH3 in identifying 
areas of mitotically active hot spots in heterogeneous 
tumors, PHH3-labeled-MFs were counted for low-power 
fields (LPF; objective 10x). Then it was compared with 
counts from 10 HPFs. Correlation between PHH3-labeled-
MFs at 10HPFs and PHH3-labeled-MFs at LPFs was high 
(Figure 3, R2 = 0.999; P = 0.001). As there was no change 
in M grade in both methods, κ statistics showed a perfect 
fit (κ = 1).
Amongst conventional clinicopathologic factors, 
PHH3 was the only factor associated with 
survival
Median follow-up was 46 months (range 2–73 
months) with seven local recurrence/metastases. Ki67 
scored for the average of four representative fields, and 
equally scored PHH3 was analyzed by Cox regression and 
Log-rank statistics. When PHH3 and Ki67 were handled 
as continuous variables, there was no significance in Cox 
regression analysis (Table 3).  However when dichotomized 
by cut-off values generated from Contal and O’quigeley’s 
method, PHH3 low and high groups was the only factor 
significantly associated with disease-free survival by 
Log-rank statistics and Cox regression univariate analysis 
(P = 0.014 and 0.043, respectively; Table 3, Figure 4), 
despite the short follow-up time; Ki67 and conventional 
clinicopathologic variables all failed to be prognostically 
significant. PHH3 low group had a mean survival time of 
57.63 months (95% CI 56.90–58.35) which was significantly 
longer than mean survival time of 56.60 months (95% CI 
54.70–58.50) for the PHH3 high group.  Hazard ratio was 
8.907 (95% CI 1.07–73.99). To compensate for censored 
events which outnumbered effective events, Harrell’s 
C-index was calculated, still establishing PHH3’s superior 
ability for prediction than Ki67 (PHH3 0.723 > Ki67 
0.645). The Akaike information criterion (AIC) was also 
calculated for Ki67 and PHH3 to determine which is more 
explanatory and informative in predicting survival. The AIC 
is a commonly used measure for comparison of competing 
models, and a smaller AIC indicates the preferred model. 
AIC of PHH3 was smaller than Ki67 (69.453 < 72.607), 
indicating better predictive ability in survival. 
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DISCUSSION
PHH3 was expressed in significantly fewer cells than 
Ki67, demonstrating better selectivity for a specific phase 
in the cell cycle. PHH3 identified easily missed mitosis 
by MAI, causing a tendency for upgrade in M grade of 
previously diagnosed cases. Between Ki67 and PHH3, 
PHH3 had significantly better reproducibility, confirmed 
by ICC. PHH3 also accurately identified mitotically 
active areas through mitotic count agreement between low 
power and 10HPFs, indicating easy recognition of mitotic 
hotspots, which would permit appropriate selection of 
fields to grade mitosis. Finally, despite a relatively short 
follow-up (median 46 months) and despite that PHH3 
was scored by Ki67 scoring method and not of its own 
mitotic counts by 10 HPFs, PHH3 was the only significant 
factor correlated with disease-free survival; conventional 
clinicopathologic variables, including Ki67, did not 
correlate with disease-free survival.
Previous studies have noted on the excellence of 
predictability of PHH3 in long term follow up; all were 
at least twice the duration of ours – the shortest reported 
Table 2: PHH3-labeled-MFs counted at 10 HPFs compared with M grade at diagnosis
Parameters Number of cases Percent (%)
down-graded 16 7.2
up-graded 29 13.2
concordance 175 79.5
Total 220 100
Figure 2: Comparison of same tumor area in H&E, Ki67 (IHC) and PHH3 (IHC). Three mitotic figures were noted by H&E 
(A) amongst apoptotic, necrotic cells - common mimickers of mitosis. Ki67 stained in various intensities (B) while the same area for PHH3 
stained a few, specific to tumor cells undergoing mitosis (C). Images were taken at 40× objective.
Figure 1: Moderately positive linear correlation between Ki67 and PHH3. Ki67 and PHH3 both had left-skewed distribution 
of data (A). Linear regression coefficient (R2) was 0.147 (P < 0.001, B).
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Table 3: Recurrence-free statistics of conventional clinicopathologic variables and Ki-67, PHH3
Parameters
Log rank statistics Cox regression, univariate analysis
Recurrence
/Total number P
Hazard ratio
(95% CI) P
Age (years) 0.388 0.524 (0.117–2.340) 0.397
≤ 50 4/87
> 50 3/126 0.255
Nuclear grade 0.240 2.386 (0.534–10.664)
1/2 4/158
3 3/55
Mitotic grade 0.663 1.392 (0.311–6.220) 0.665
1 4/134
2/3 3/79
Histologic grade 0.451 1.504 (0.543–4.165) 0.433
I 2/61
II 2/98
III 3/54
Tumor stage 0.537 1.594 (0.357–7.125) 0.541
T1 4/146
T2/T3 3/67
Nodal metastasis 0.780 1.271 (0.246–6.549) 0.781
Absent 5/163
Present 2/50
Estrogen receptor 0.585 0.631 (0.122–3.255) 0.588
Negative 2/46
Positive 5/167
Progesterone receptor 0.582 0.659 (0.148–2.946) 0.594
Negative 4/105
Positive 3/113
HER-2 status 0.994 0.957 (0.115-7.950) 0.994
Negative 6/181
Positive 1/32
Molecular subtype 0.186 1.501 (0.729-3.089) 0.270
Luminal A 1/103
Luminal B 4/64
HER-2 2/34
TNBC 0/12
Ki-67 (cut-off: 43.0%) 0.343
Low 5/179
Continuous
1.019 (0.988–1.052) 0.227
High 2/34
Categorical (Low vs. High)
1.365 (0.265–7.035) 0.356
PHH3 (cut-off: 0.30%) 0.014
Low 1/127
Continuous
1.827 (0.556–5.999)
0.321
High 6/86
Categorical (Low vs. High)
4.826 (1.080–21.567)
0.043
Oncotarget65070www.impactjournals.com/oncotarget
being 85 months and the longest, 168 months (14 years)
[19, 21–23]. Skaland et al. studied node-negative invasive 
breast cancers in patients less than 55 years old treated 
with adjuvant systemic chemotherapy with follow-up of 
median 168 months [22]. Gerring et al. compared Ki67 
with PHH3 on TMAs and discovered that PHH3 was a 
stronger predictor of survival than Ki67 with median 
follow-up of 85 months [19]. For premenopausal node-
negative breast cancer patients, PHH3 was also significant 
for survival with median follow-up of 10.8 years [21]. Our 
study is notable in that PHH3 demonstrated as a significant 
marker of survival even in such short term follow up, 
shortest reported so far. 
In this study, direct comparison of PHH3 with the 
existing marker Ki67 was possible because PHH3 was 
scored according to Ki67 scoring method; standardized 
Ki67 scoring of average percentage of positive cells in 
four representative fields, was equally applied on PHH3. 
However, it should be noted that in practice, it is unusual 
to score PHH3 in terms of Ki67. PHH3 is essentially a 
mitotic marker, usually scored by counting mitosis in 
10 HPFs. In this study, for fair comparison PHH3 was 
scored by the Ki67 scoring method, which does not 
capture the full potential of PHH3 in its coverage of 
mitosis. Therefore, in this study, the predictive power 
of PHH3 is likely to have been undermined, but despite 
of these limiting conditions, it is noteworthy that it still 
outperformed Ki67 in survival prediction.
Surprisingly, none of the clinicopathologic variables, 
including M grade and H grade correlated with Ki67 or 
PHH3. This finding may prove the more subjective nature 
of mitotic grading, which also influences histologic grade. 
Also, because breast cancer prognosis is multifactorial 
[1], it may not be necessary for PHH3 to correlate with 
known clinicopathologic variables, which are rarely 
independently useful to evaluate prognosis of breast 
cancer. Furthermore, in our study, M grade and H grade 
did not correlate with neither log rank nor cox regression 
survival statistics while PHH3 did, verifying that PHH3 is 
clinically more relevant than the traditional H&E mitotic 
grading (MAI).
Ki67 and PHH3, both IHC markers, allow 
convenient distinction between positive and negative 
cells. Problems of reproducibility of Ki67 concerned 
interpretational variations in stain intensities as well as 
selection of fields in heterogeneous breast cancers [24]. In 
contrast, PHH3 offers a unique feature of reconfirmation 
of mitosis by morphology (condensed chromatin), 
Figure 3: Scatter plot for PHH3-labeled-MFs x10 HPFs and PHH3-labeled-MFs at LPFs. There was a strong linear 
correlation between PHH3-labeled-MFs counted at 10 HPFs and PHH3-labeled-MFs counted at LPFs (four LPFs in approximate area 
equivalent to 10HPFs); linear regression coefficient R2 = 0.999, P = 0.001.
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allowing better agreement as well as accuracy of detection 
[14]. In light of this advantage, PHH3 has been reported to 
closely match with mitotic index [18, 25]. 
Ki67 use in breast cancer diagnostics has been 
disputed for inadequate representation of proliferation and 
poor inter-rater reproducibility. Ki67 may be unsuitable to 
represent proliferation as it marks all cells in the cell cycle, 
except for G0 phase. Several studies have shown that G1 
phase cells had uncertain destinies, therefore inclusion of 
G1 would be inaccurate to measure proliferation [6–8]. 
However, the more widely recognized flaw of Ki67 is 
low inter-rater reproducibility. Especially problematic in 
heterogeneous breast cancers, much of the problem was 
credited to a lack of scoring consensus amongst experts; 
some advocate selective use of hotspots in assessment of 
Ki67 while others favor taking average of the invasive 
front [20]. Yet, even after standardization of the 2011 
International Ki67 in Breast Cancer Working Group, 
which recommended taking the overall average of tumor, 
including hotspots [5, 20], problems in reproducibility 
was consistently reported. No single factor (counting 
method, threshold for positivity, area chosen to score, 
or staining methodology) explained the cause of low 
reproducibility of Ki67, according to the International Ki67 
Reproducibility Study of 2013 [26]. This multicenter study 
reported there was substantial variability in inter-laboratory 
reproducibility demonstrated by moderate ICC with a wide 
ranged 95% CI (central staining: ICC = 0.71, 95% CI = 0.47 
to 0.78; local staining: ICC = 0.59, 95% CI = 0.37 to 
0.68), which concluded the clinical utility of Ki67 in 
breast cancer to be “elusive”. Another study reported high 
variability among 15 pathologists in assessing three breast 
carcinoma cases (κ 0.04–0.14) [27]. Ki67’s poor kappa 
score was contrasted to the excellent kappa score of a 
different study assessing reproducibility of PHH3 among 
three pathologists (κ  0.87, 0.79, 0.76) [18]. 
Our study confirmed those very limiting factors 
of Ki67 which contributes to low reproducibility. 
We demonstrated Ki67 staining with wide range in 
intensities; depending on the rater, the threshold for 
positive cells would be set differently. In contrast, PHH3 
displayed little variations in expression intensities and 
only counted for strongly stained cells then reconfirmed 
by morphology, which allows accuracy and consistency 
amongst raters. Reproducibility was tested by inter-rater 
agreement test of Ki67 and PHH3 on hot spots, where 
indeed Ki67 had a significantly lower ICC than PHH3 
(0.701 < 0.904; P = 0.008). 
We also demonstrated PHH3 to have better 
sensitivity for detecting mitosis than MAI; there was a 
Figure 4: Disease-free survival shown by Kaplan–Meier curve. Total of 213 cases (5 cases lost in follow up) were divided into 
PHH3 low and high groups. High PHH3 expression (> 0.03%) was significantly associated with shorter recurrence-free survival (mean 
survival time, 56.60 months < 57.63 months).
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tendency for up-grading of M grade when re-evaluated 
by PHH3. LPF assessments also correlated well with HPF 
enumerations signifying that mitotically active areas could 
be located in low power, resolving the weakness of MAI, 
which is impossible to identify mitotically active areas 
properly for accurate measurement of mitosis. Aside from 
the current study of breast cancers, meningioma is another 
tumor where mitosis is important for tumor grading where 
PHH3 proved to produce rapid, reliable grading [13, 28].
PHH3 targets cells in mitosis, therefore should 
theoretically match with mitotic counts determined by 
microscopic analysis of the H&E-stained slide. However, 
M grade counted by PHH3 did not always match with the 
M grade counted on H&E (MAI). A possible explanation 
for the discrepancy is the subjectivity associated with 
mitotic activity index and inaccurate localizations of 
mitotically active areas [28–30]. On a similar note, studies 
noting superior survival correlations of Ki67 compared 
to mitotic index may be explained by possible masked, 
unidentified mitosis which may have underestimated the 
actual proliferative potential of mitotic index [31, 32]. 
Our study demonstrated the underestimation of mitotic 
power on H&E (MAI) through upgraded M grades by 
PHH3. In addition, survival statistics proved M grade 
insignificant in prognostication, in contrast to PHH3 which 
was significantly associated with disease-free survival. 
These findings suggest that the M grade evaluated by 
conventional H&E microscopic analysis (MAI) may 
not fully represent a tumor’s proliferative potential. In 
addition, a recent study demonstrated excellent correlation 
between disease-free-survival and Nottingham M grade 
using PHH3 [25]. Supported by these findings, PHH3 
may improve M grade accuracy of the Nottingham grading 
system through better identification of mitosis.
 In a comparable study by Gerring et al. [19], PHH3 
was also superior to Ki67 in predicting patient survival. 
However, their study had longer follow-up (median 85 
months; maximum 191 months) with more accumulated 
data for survival analysis (54 deaths out of 108 patients). 
Despite the advantage of long follow-up, the study tested 
on TMAs, which does not address the dilemma of tumor 
heterogeneity in every-day breast cancer diagnostics. Our 
study was representative of the actual diagnostic practice 
by using surgical slides and demonstrated meaningful 
associations with survival in a notably short follow-up 
period of median 46 months. Taken together, our study 
provides stronger evidence that PHH3 is a superior 
prognostic marker to Ki67.
 To our knowledge, this is the first study that addresses 
all problems associated with conventional markers of 
proliferation (MAI and Ki67) and highlights advantages 
of PHH3. PHH3 is specific to mitosis and reliably 
discriminates true proliferating cells from proliferation-
mimicking cells, a notable advantage compared to MAI or 
Ki67. It is particularly valuable in heterogeneous tumors 
because it accurately identifies mitotically active areas with 
discrete expressions, permitting good agreement among 
raters. Our study confirms PHH3’s ability to accurately 
measure proliferation, through its clinical importance as the 
only marker amongst known clinicopathologic variables to 
correlate with survival. 
Ki67 and MAI have been the mode of evaluating 
breast cancers despite flaws in reproducibility for there 
had been no better alternative. Findings of our study 
advocate the routine use of PHH3 in diagnostics to 
reinforce weaknesses of existing markers.
Limitations
Short follow-up limited robustness of analysis with 
only seven recurrences and could not analyze for overall 
survival. As mentioned in Methods, cases of small sizes 
were excluded, which may have caused selection bias. 
Immunostaining may have been affected by pre-
analytical conditions and antigen preservation. Although 
MAI has been known to be relatively unaffected by fixation 
conditions, PHH3 and Ki67, both immunohistochemical 
stains, would be affected by fixation conditions. 
Reproducibility study based on five raters was 
limited as these were pathologists from the same institution 
with similar training. Therefore, our reproducibility study 
may not fully represent the general cohort of pathologists. 
In addition, sample size of five rater inter-rater agreement 
was limited to 30 cases; evaluation under the microscope 
takes substantial time and effort while the generally 
accepted number which allows sufficient weight in 
analysis in inter-rater agreement is as few as 30 cases. 
For direct comparison with Ki67 for expression 
qualities, clinicopathologic characteristics, including 
survival analysis, PHH3 was evaluated for the same fields 
previously selected by Ki67. Therefore, our results of 
PHH3 having strong significance in survival implies that 
assessment of PHH3 requires an initial selection of scoring 
fields by Ki67 to predict prognosis. For these reasons, 
though PHH3 proved to be an independent prognostic 
variable, possibly most important amongst conventional 
clinicopathologic markers, its independent application 
in breast cancer diagnostics merits further study. For 
now, we advocate the routine use of PHH3 in breast 
cancer diagnostics in conjunction with Ki67 to improve 
prediction of disease-free survival.
MATERIALS AND METHODS
Patient selection and clinicopathologic analysis
This retrospective study was approved by the 
Institutional Review Board (IRB) of Yonsei University 
Severance Hospital. 218 surgical tissues from 216 donor 
patients who had invasive ductal cancer, not otherwise 
specified, diagnosed and surgically resected at Severance 
Hospital from January 2012 to December 2013 were 
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analyzed. All tissues were fixed in 10% buffered formalin 
for 48 hours then embedded in paraffin. All archival H&E-
stained slides from all cases were reviewed by a breast 
pathologist (Koo JS). Cases treated with pre-operative 
chemotherapy or radiotherapy was excluded. Also, cases 
with tumor size smaller than 0.5cm were excluded, as 
considered too small to generate four HPFs for evaluation. 
Included clinical parameters were patient age at initial 
diagnosis, tumor stage, nodal metastasis, tumor recurrence 
and deaths. Histological grade was assessed by the 
Nottingham grading system [33]. 
Immunohistochemistry (IHC)
Antibodies used for IHC are listed in Supplementary 
Table 1. All IHC was performed with formalin-fixed, 
paraffin-embedded tissue sections. Briefly, 5-μm-thick 
sections were obtained with a microtome, transferred onto 
adhesive slides, and dried at 62°C for 30 minutes. 
Using the Discovery XT automated 
immunohistochemistry stainer (Ventana Medical Systems, 
Inc., Tucson, AZ, USA), slides were stained as the 
following procedure. Detection was done using the Ventana 
DAB Map Kit (Ventana Medical Systems).
Tissue sections were deparaffinized using EZ Prep 
solution. CC1 standard® (pH 8.4 buffer containing Tris/
Borate/EDTA) was used for antigen retrieval. Inhibitor 
D® (3% H2O2, Endogenous peroxidase) was blocked 
for 4 min at 37°C temperature. Slides were incubated 
with primary antibodies (PHH3, Polyclonal, 1:100, 
Cell Marque, Rocklin, CA, USA; anti-Ki67 antibodies, 
clone MIB-1, DAKO, Glostrup, Denmark) for 40 min 
at 37°C, and a secondary antibody of biotinylated anti-
mouse immunoglobulin for 20 min at 37°C. Slides were 
incubated in SA-HRP D® (peroxidase-labeled streptavidin 
using a labeled streptavidin biotin kit) for 16 min, at 37°C 
and then 3,3′-diaminobenzidine chromogen combined 
H2O2 substrate for 8 min followed by Harris hematoxylin 
and bluing reagent counterstain at 37°C for 4 minutes. 
Reaction buffer (pH 7.6 Tris buffer) was used as washing 
solution. Tonsilar tissue was used for both positive and 
negative controls.
IHC interpretations
All IHC markers were assessed by light microscopy. 
A cut-off value of 1% or more positively stained nuclei was 
used to define ER and PR positivity [34]. HER-2 staining 
was analyzed according to the American Society of Clinical 
Oncology (ASCO)/College of American Pathologists 
(CAP) guidelines using the following categories: 0 = no 
immunostaining, 1+ = weak incomplete membranous 
staining in less than 10% of tumor cells, 2+ = complete 
membranous staining, either uniform or weak in at least 
10% of tumor cells, and 3+ = uniform intense membranous 
staining in at least 30% of tumor cells [35]. HER-2 was 
considered positive when strong (3+) membranous staining 
was observed, whereas cases with 0 to 1+ scores were 
regarded as negative. Cases showing 2+ HER-2 expression 
were further evaluated for HER-2 amplification by 
fluorescence in situ hybridization (FISH).
Tumor phenotype classification
Breast cancer phenotypes classified according to 
IHC results for ER, PR, HER-2, Ki67, and FISH results 
for HER-2 as follows [36]. Luminal A, ER or/and PR 
positive, HER-2 negative and Ki67 labeling index (LI) 
< 14%; luminal B (HER-2 negative), HER-2 negative ER 
or/and PR positive, HER-2 negative and Ki67 LI ≥ 14%; 
luminal B(HER-2 positive), ER or/and PR positive and 
HER-2 overexpressed or/and amplified; HER-2 enriched, 
ER and PR negative and HER-2 overexpressed or/and 
amplified; and TNBC, ER, PR, and HER-2 negative. 
Selection of fields
Ki67 was examined first to select appropriate 
fields. Four HPFs (objective 40x) that best represented 
the overall tumor were selected from the invasive front, 
in the manner recommended by the International Ki67 in 
Breast Cancer Working Group [20]. When hot spots were 
present, these were included in the overall average score. 
The same four fields were appropriately marked for PHH3 
(Supplementary Figure 1). Each field of examination 
was photographed to assure consistency of the field of 
examination at a given time.
Tumor cells were counted manually using the 
counter application of publicly available image analysis 
program, Image J. 
Scoring Ki67 and PHH3
In scoring Ki67, tumor cells were considered 
positive for only strongly stained nuclei, which were 
clearly above the background level, in keeping with 
previous studies [3]. Intact nuclei with fine granular 
staining of PHH3 were not counted as these cells were not 
in mitosis, but only strongly stained cells with mitogenic 
morphology was counted [37]. A percentage score was 
obtained by dividing the number of positively stained cells 
by the total number of cells. The final percentage score 
was the average of four fields. 
Inter-rater reproducibility study of five raters
Five pathologists working in the same institute 
participated in the inter-rater reproducibility study of 
Ki67 and PHH3 for 30 cases. H&E slides of the IHC 
stained slides were jointly provided for reference before 
scoring each case. Each participant’s ratings were made 
independently without knowledge of each other’s ratings 
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as each test was conducted at different times without one 
knowing who was participating in this study. The first author 
gave same instructions for each participant and monitored 
the progress. There were no chances of discussion amongst 
participants. All are qualified pathologists who are reporting 
actively on cancer biomarker results.
Statistical analysis
Data were analyzed using SPSS for Windows, 
Version 21.0 (SPSS Inc., Chicago, IL, USA), SAS, Version 
9.4 (SAS Institute Inc., SAS Campus Drive, Cary, North 
Carolina 27513, USA), R statistics, Version 3.2.2 (The R 
Foundation for Statistical Computing, Vienna, Austria). 
Ki67 and PHH3 scores were calculated as categorical 
variables. For determination of statistical significance Chi 
square cross analysis was used for dichotomous variables. 
Correlation was analyzed by linear regression analysis. 
For inter-rater agreement, ICC and Cohen’s κ statistics 
were used where ICC was used to assess inter-rater 
reliability for numeric variables while Cohen’s κ was used 
to assess inter-rater reliability for categorical variables. 
ICC was compared for PHH3 and Ki67 according to 
their corresponding different scoring methods using the 
same cases, using comparison test of dependent ICC 
(Supplementary Figure 2) [38]. Cut-off determination by 
Contal and O’Quigely’s method was performed on SAS. 
The AIC and Harrell’s C-index was calculated for Ki67 
and PHH3 each, on R statistics. Statistical significance 
was set to P < 0.05. Kaplan–Meier survival curves and 
log-rank statistics were used to evaluate time to tumor 
recurrence. Cox proportional hazards model was used for 
univariate regression analysis.
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